ProMIS NeurosciencesのBeta
ProMIS NeurosciencesのBetaは何ですか。
ProMIS Neurosciences, Inc.のBetaは1.04です。
Betaの定義は何ですか。
BETAは、株式が市場全体よりも多かれ少なかれ揮発性であるかどうかを示します。 1未満のベータは株式が市場よりも揮発性が低いことを示し、1より大きいベータは株式がより揮発性であることを示します。ボラティリティは、平均値周辺の価格の変動として測定されます。
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
OTCのセクタHealth CareにおけるBetaの企業と比べるProMIS Neurosciences
ProMIS Neurosciencesは何をしますか。
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
ProMIS Neurosciencesと類似のbeta
- Shree Hari Chemicals ExportのBetaは1.04です。
- Bajaj & InvestmentのBetaは1.04です。
- GHW InternationalのBetaは1.04です。
- Pharming N.VのBetaは1.04です。
- Pharming N.VのBetaは1.04です。
- abrdn Australia Equity Fund IncのBetaは1.04です。
- ProMIS NeurosciencesのBetaは1.04です。
- Theriva Biologics IncのBetaは1.04です。
- Bank of HawaiiのBetaは1.04です。
- SEACOR IncのBetaは1.04です。
- Mercantile BankのBetaは1.04です。
- Sa Sa InternationalのBetaは1.04です。
- Bharat ForgeのBetaは1.04です。